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Revealed in Normal Tissue
Selina Vattathil1,2,3,* and Paul Scheet1,2
Genomic mosaicism arising from post-zygotic mutation has recently been demonstrated to occur in normal tissue of individuals ascer-
tained with varied phenotypes, indicating that detectable mosaicism may be less an exception than a rule in the general population.
A challenge to comprehensive cataloging ofmosaicmutations and their consequences is the presence of heterogeneousmixtures of cells,
rendering low-frequency clones difficult to discern. Here we applied a computational method using estimated haplotypes to characterize
mosaic megabase-scale structural mutations in 31,100 GWA study subjects. We provide in silico validation of 293 previously identified
somatic mutations and identify an additional 794 novel mutations, most of which exist at lower aberrant cell fractions than have been
demonstrated in previous surveys. These mutations occurred across the genome but in a nonrandommanner, and several chromosomes
and loci showed unusual levels of mutation. Our analysis supports recent findings about the relationship between clonal mosaicism and
old age. Finally, our results, in which we demonstrate a nearly 3-fold higher rate of clonal mosaicism, suggest that SNP-based population
surveys of mosaic structural mutations should be conducted with haplotypes for optimal discovery.Although post-zygotic mosaic mutations have been tradi-
tionally associated with cancer, they have recently been
invoked in explanations of pathways of other diseases
as well. For example, ‘‘selfish selection’’ in spermatogonial
cells for clones carrying certain activating mutations
of genes in the MAPK/RAS pathway provides a parsimo-
nious explanation for the paternal age effect for several
RASopathies and neurodegenerative disease.1 Another
example is the observation that individuals with type 2
diabetes (T2D) have a 5-fold higher risk of bloodmosaicism
than individuals without T2D and that the risk is even
higher in the subset of T2D individuals with vascular com-
plications, suggesting that the ‘‘accelerated aging’’ pheno-
type associated with T2D may be the secondary conse-
quence of genetic instability mediated by inflammation.2
On the other hand, multiple recent large-scale studies
have revealed that apparently healthy individuals harbor
detectable mosaic mutations; the frequencies are low in
young individuals but increase to frequencies of 2%–3%
in elderly (> 70þ years) individuals.3–6 These rates repre-
sent the detectable mutations only.
These examples and others7–10 highlight that mosaic
mutations create a spectrum of phenotypes, in addition
to being a prognostic indicator for hematological cancer
risk (in blood samples),3 and that the effect of any partic-
ular mutation depends on multiple factors, such as the
cell type in which it arises and the number of cells carrying
the mutation. A detailed picture of the landscape of so-
matic mosaic mutations, i.e., their prevalence among indi-
viduals as well as their frequencies among cells of specific
tissues, is therefore of significant value. The low end of
the intra-tissue frequency spectrum might be the most
dense and dynamic, given that all mutations will start
out at very low frequency and some mutations might be1Department of Epidemiology, The University of TexasMDAnderson Cancer C
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is difficult to detect mutations at low frequency by agnostic
whole-genome methods, and it is widely acknowledged
that mosaic mutations in the low end of the frequency
spectrum have been under-characterized.
The goal of our study was to investigate the prevalence
of low-frequency somatic structural mosaicism in healthy
tissue by applying a haplotype-based method to SNP array
data from 31,100 individuals. Several reports have cited
the potential increase in sensitivity from using haplotype
information.11,12 Below, we summarize the genomic
locations of our discovered aberrations and describe
characteristics of these aberrations in comparison to those
discovered in a previous analysis of these data, and we
report on the association between risk of mosaicism
and age.
We obtained SNP microarray data from ten large
genome-wide association studies (Table S1) that were all
previously analyzed for somatic structural mosaicism by
the GENEVA consortium.3 These were case-control
studies investigating the role of genetic variation and
gene-environment interaction in a wide range of disease
phenotypes, including cancer and non-cancer pheno-
types. To these data we applied hapLOH13 for an orthog-
onal assessment of mosaicism due to acquired chromo-
somal mutations that create allelic imbalance, or a
departure from the inherited 1:1 ratio of maternal and
paternal alleles. The method targets segmental (mega-
base-scale to whole-chromosome) alterations by using a
powerful and robust haplotype-based approach to sensi-
tively detect somatic hemizygous deletions, copy-neutral
loss of heterozygosity (CNLOH), and duplications (collec-
tively, somatic chromosomal and copy-number alter-
ations, SCNAs).enter, Houston, TX 77030, USA; 2The University of Texas Graduate School of
, Seattle WA 98195, USA
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Figure 1. BAF and LRR Deviations per SCNA
The pink lines indicate the expected values for mosaic hemizygous
deletions (lower line), mosaic CNLOH (middle horizontal line),
and mosaic single-copy duplications (upper line) for aberrations
present in 10% to 100% of the sampled cells (dashes are at 10%
increments). The gray shaded area indicates the area within the
thresholds used to define an SCNA as a copy-number gain or
copy-number loss. Each point is colored according to the copy-
number classification on the basis of these deviations.The DNA samples were collected from blood or buccal
cells, or from blood-derived cell lines, and were genotyped
with Illumina arrays. Genotypes, B allele frequencies
(BAFs), and log R Ratios (LRRs) were downloaded from
dbGaP (study accession numbers: Table S1). We considered
data from bi-allelic SNP markers from both case and con-
trol samples after applying basic quality-control proce-
dures. Specifically, we excluded duplicate samples, samples
derived from whole-genome-amplified DNA or cell-line
DNA, or samples with a LRR waviness score wf (calculated
with PennCNV14) such that jwf j > 0:04. Within each
study, we excluded markers with a missing rate greater
than 10% or that departed from Hardy-Weinberg propor-
tions (Chi-square or exact test p value < 105).
Genotypes were phased with fastPHASE15 or Beagle.16
The hapLOH hidden Markov model (HMM) was set to 2
states. Transition parameters for each sample were set to
correspond to an expected imbalance event size of 20 Mb
and a genome-wide imbalance rate of 0.1%. We performed
two runs of the EM algorithm with starting values for
the emission probabilities defined as (pn, pn þ 0.05) and
(pn, 0.95), where pn is the sample-specific average phase
concordance rate calculated from all informative (germline
heterozygous) markers. Each EM run continued until the
log-likelihood increasewas smaller than 0.0001 (usually be-
tween 4 and 20 iterations), and the parameter set with the
highest likelihood was used for calculating posterior proba-
bilities. To create a list of discrete event calls, we applied a
threshold of 0.95 to the probability of being in the aberrant572 The American Journal of Human Genetics 98, 571–578, March 3state and defined an event as a run of intervals with proba-
bilities exceeding this value. We used a three-state HMM to
reanalyze samples with an event call to improve discovery
in samples with multiple events at possibly varying levels
of imbalance. The start and end base positions for each
SCNAwere defined by the left-side marker of the first inter-
val and the right-side marker of the last interval of the run.
We applied additional quality filters after obtaining
output from hapLOH. First, we excluded samples with
values > 0.52 for a0, the HMM emission parameter corre-
sponding to the ‘‘normal’’ state. Elevated values of this
parameter might indicate a sample-level quality issue,
such as a low level of inter-sample contamination, that
could create a false positive signal of mosaicism. We also
excluded any events overlapping the HLA region (genomic
coordinates chr6: 29,677,984–33,485,677, taken from17)
because the BAF and LRR data from markers in this region
show atypically high variation and might not be reliable.
For one sample, more than 75% of the genome was called
as imbalance. This sample is most likely a case of inter-sam-
ple contamination but did not fail the a0 threshold. We
excluded this sample from analysis. We also excluded
four calls that had fewer than 15 informative markers
and were artifacts of the calling procedure.
We calculated a BAF and LRR deviation for each discrete
event call that passed the above quality-control steps.
These data types can be considered a function of the spe-
cific SCNA type and the proportion of cells harboring the
alteration in the sample. The BAF deviation was defined
as the average of the absolute value of the differences be-
tween the median heterozygote BAF for the sample and
the heterozygote BAFs within the event call. The LRR devi-
ation was defined as the average difference between the
median LRR for the sample and the LRRs within the event
call. We used the observed deviations to identify 1,507
calls from the preliminary set as likely inherited duplica-
tions and removed these from subsequent analyses.
Specifically, we applied a simple thresholding procedure
to classify calls with LRR deviation > 0.08 and BAF devia-
tion < 0.10 as likely inherited duplications. We expect
that with this procedure we might misidentify some true
high-frequency somatic events as inherited duplications;
we accept this loss of sensitivity to maintain specificity.
The remaining calls are putative SCNAs.
We identified 1,141 unique SCNAs in 901 of 31,100 sam-
ples (2.9% of samples). Those with LRR deviation> 0.05 or
LRR deviation < 0.05 were classified as gains or losses,
respectively. The remaining calls included the CNLOH
events and events involving very low cell fractions, for
which we expect the LRR deviation will be small even
if there is a copy-number change. Events with BAF devia-
tion > 0.1 were classified as CNLOH, and the remaining
events (with small LRR deviation and small BAF deviation)
were left as ‘‘undetermined.’’ Of the 1,141 SCNAs, we clas-
sified 70 as single-copy gain, 202 as hemizygous loss, and
30 as CNLOH and left 839 unclassified (Figure 1). Ninety-
four (94) samples (0.3%) exhibited two SCNAs, and 44, 2016
Figure 2. SCNAs by Chromosome
The red shading on each ideogram indicates the range of the plottedmutations. SCNAs are plotted as horizontal bars, colored by inferred
copy-number: red, loss; green, CNLOH; blue, gain; and gray, undetermined. A thin line connecting SCNAs within a chromosome indi-
cates the SCNAs occur in the same sample.samples (0.14%) exhibited three or more SCNAs; one
exhibited 18 SCNAs that ranged in size from less than
0.3 Mb to 92 Mb. These 138 subjects carrying multiple
SCNAs represent a 5.3-fold enrichment over what would
be expected by chance, consistent with the existence of in-
dividual-level factors that affect the likelihood of observing
a mutation. SCNA locations are presented in Table S2.
The rate of mutation and inferred copy numbers of
SCNAs varied substantially by genomic region (Figure 2).
As a measure of the local mutation rate, we compared
the SCNA overlap count for each gene for 24,383 genes
(we used the largest transcript from RefSeq18 to represent
gene location). For this assessment, we used the SCNAs
observed in the 26,927 blood samples only (we excluded
buccal samples and samples without annotation on
DNA source) because aberration patterns might differ by
tissue. Only 1,318 genes were not covered by an SCNA
in any of the samples. The most frequently overlapped
gene was PTPRT (MIM: 608712) on chromosome 20,
which was overlapped in 60 samples; nearby genes inThe Amethe surrounding region had the next highest overlap
counts. Multiple chromosomes exhibited similar sharp
peaks in SCNA overlap counts (Figure S1 and Table S3),
the most notable being chromosome 13, which had a
peak overlap count of 49 SCNAs covering the contiguous
genes DLEU1 (MIM: 605765) and DLEU7. Other chromo-
somes showed broader peaks in SCNA overlap counts.
For example, 17 contiguous genes on chromosome 14
were overlapped by SCNAs in 57 samples. Chromosomes
5, 6, 10, and 16 had the lowest SCNA overlap counts,
and indeed the fewest counts in general; fewer than ten
SCNAs covered any gene.
In a recent meta-analysis of SNP array data from more
than 127,000 subjects, Machiela et al.5 reported that
SCNAs aggregated on chromosomes by copy number.
They cited chromosomes 8, 12, and 15 as carrying the
majority of somatic gains, chromosomes 13 and 20 as
carrying the majority of somatic losses, and chromosomes
9 and 14 as carrying the majority of somatic CNLOH.
They also pointed out that focal deletions on 13q andrican Journal of Human Genetics 98, 571–578, March 3, 2016 573
Figure 3. Phase Concordance versus Genomic Size
The circles and diamonds represent SCNAs called by hapLOH
only, Laurie et al. only, or both in samples that were included in
both analyses. Many of the SCNAs called by Laurie et al. only
had few or no heterozygous calls, so the phase-concordance values
were incalculable or imprecise; all of these were plotted with phase
concordance ¼ 1. The triangles represent the calls made in the
simulated null samples.20q are frequent. As we describe below, many of the SCNAs
we observed are low frequency (carried in a small propor-
tion of cells) and do not create strong enough deviations
in the BAF and LRR data to allow determination of copy
number. However, most recurrent loci (those at which
SCNAs were observed at relatively high frequency) that
harbored SCNAs with determinable copy number demon-
strated a particular mutation type. For example, we
observed deletions on chromosomes 13 and 20 in regions
that are commonly deleted in hematological cancer, and
we observed multiple instances wherein the entire chro-
mosome 12 was duplicated, in accord with previous
studies.3–5 We also observed large chromosome 15 duplica-
tions that span at least the entire q arm, or possibly the
entire chromosome (these two possibilities are indistin-
guishable in our data because none of the SNP arrays
included markers on the p arm). Some loci do harbor
classifiable SCNAs of multiple copy-number classes; for
example, at 14q (or possibly the entirety of chromosome
14) we observe both duplications and CNLOH.
A large subset of our dataset (30,208 samples) was
analyzed previously for SCNAs by a different method.3
Laurie et al. applied a method designed for discovering
SCNAs on the basis of the magnitude of BAF and LRR
deviations (without using haplotype information). Within
samples common to both analyses, our analysis identified
far more SCNAs (1,093 versus 379). We used the genomic
positions to define the extent of overlap between hapLOH
and Laurie et al. calls in these samples. More than 90% of
overlapping events had more than 80% overlap with
events in the other analysis, although there were instances
in which one analysis called one event but the other split
the same region into multiple events, so that the overlap
with an individual event could be low but the total overlap574 The American Journal of Human Genetics 98, 571–578, March 3when all overlapping events were considered was high. To
make a comparison of the sets of calls in the two analyses,
we deemed calls to be concordant if they had any overlap
with sample-specific calls in the other analysis and ignored
copy-number classifications, although our conclusions do
not change qualitatively for other overlap criteria (Table
S4). Using these criteria, we classified 299 hapLOH SCNAs
and 293 Laurie et al. SCNAs as concordant (the counts are
not equal because some calls overlapped multiple calls in
the other analysis). A total of 794 SCNAs were unique to
our analysis, and 86 SCNAs were unique to Laurie et al.
Ten of the SCNAs unique to Laurie et al. were part of the
initial hapLOH call set but were excluded as possible in-
herited duplications or because they overlapped the HLA
region. Another 33 of the SCNAs were short (spanning
fewer than 200 markers, mean size 415 Kb), and for the re-
maining 43 SCNAs the mutant cell fraction was high
enough that that there were almost no called heterozygous
genotypes, upon which our method is based; thus, these
mutations were outside the range of events targeted in
our analysis. hapLOH uses phase concordance (a measure
of the switch accuracy between the statistical haplotypes
and the BAFs; see Vattathil and Scheet13) to detect SCNAs.
The observed phase concordance is a function of several
factors, including the copy number of the mutant cells,
mutant cell fraction, and the accuracy of the statistical
phasing, yet can roughly be interpreted as a level of allelic
imbalance created by the mutation, particularly at lower
cell fractions. All of the SCNAs present in both call sets
had phase concordance exceeding 0.8, whereas three-
fourths of the SCNAs uniquely identified in our analysis
had phase concordance values less than 0.8 (Figure 3).
This is in line with expectations because the haplotype-
based method we employed is especially sensitive for
low-cell-fraction SCNAs.
An important characteristic of our method is that the
sensitivity increases with both the magnitude of the phase
concordance and the size of the event (in terms of number
of heterozygous genotypes). SCNAs inducing subtle allelic
imbalance are therefore detectable, but only if their size is
large enough. The lack of SCNAs in the lower left corner of
Figure 3 demonstrates this point. By the same token, short
regions are detectable, but only if the phase concordance is
high enough (upper left corner of Figure 3). The sensitivity
for short events is also restricted in this analysis by the spe-
cific parameter settings we employed; we did not enforce a
minimum size threshold for SCNA identification but chose
parameters that would provide sensitivity for subtle events
yet keep the false-positive rate low. Using this setting, one
can identify kilobase-range SCNAs, but probably only
when the phase concordance is high. We expect that
many SCNAs with low phase concordance exist at small
genomic size, but our analysis was not designed for their
discovery.
One question regarding low-cell-fraction events is
whether they occur randomly across the genome or
show spatial and copy-number patterns similar to, 2016
those of higher-cell-fraction events. To address this, we
looked at the location and copy-number assignments of
hapLOH-exclusive calls (Figure S2). We considered only
calls in blood samples, as we did for the spatial-distribution
analysis of the total call set. Out of the 698 hapLOH-
exclusive calls in blood samples, only 74 were assigned a
copy number (56 gains, 18 deletions, and 0 CNLOH).
These included five deletions on 13q and four deletions
on 20q that overlapped the commonly deleted regions
reported by Machiela et al. One gene on chromosome 7,
MTRNR2L6, also was overlapped by a deletion in four sam-
ples. These were the most common recurrent deletions in
this set. No region was overlapped by more than two gain
events. To get a rough sense of how well our 624 ‘‘undeter-
mined’’ calls match the Machiela et al. set in terms of chro-
mosomal aggregation by copy number, we calculated the
average LRR deviation per chromosome for these calls.
The averages are consistent with the copy-number distri-
bution by Machiela et al.—chromosomes 8, 12, and 15
showed the highest average LRR deviation for undeter-
mined calls, whereas chromosomes 10, 13, and 20 showed
the lowest average LRR deviation. Of note, chromosome
10 had the fewest calls (16), so sampling variation might
explain its unexpected ranking.
We used the observed BAF and haplotype data to
perform a permutation-based simulation to estimate the
false-positive rate of the method. Specifically, for each of
the 31,328 samples that passed our initial quality-control
steps, we permuted the observed BAFs at the informative
markers (that is, the subset of markers at which the sample
had heterozygous genotype calls; this subset was unique
for each sample), and then applied our analysis protocol
to these data. Permuting the BAFs at informative markers
disrupts the dependence in the BAF deviations that would
arise from somatic imbalance while preserving the level
of random variation originally present in the data. So,
any calls made in these ‘‘simulated null’’ samples represent
false positives arising from chance stretches of increased
phase concordance. Because there could be other sources
of false positives (although we have attempted to rule
these out by quality-control procedures), the call rate
estimated here is effectively a lower bound on the false-
positive rate. Application of our analysis protocol to data
generated from a single permutation of each of the
31,328 samples yielded 25 SCNA calls in 25 samples, or
about 0.08% of samples. Thus, the rate of 2.9% we
observed in the original data represents an approximately
37-fold enrichment over the estimated null rate and a false
discovery rate of <3%. The 25 calls in the permuted data
display a very different distribution in terms of phase
concordance and genomic size than the calls from the
real data (Figure 3); they reside along a gradient of lower
values for these features. Therefore, in practice this false-
discovery rate will vary as a function of attributes of the
event call. Of note, none of the simulated null samples
failed the a0 -based quality-control filter, which is the
expected result if elevated a0 values reflect biologicalThe Amecontamination and are not simply due to poor parameter
estimation.
Because the BAF and LRR deviations depend on the
mutant cell fraction, we could theoretically attempt to
infer this quantity for each SCNA. However, just as with
the inference of copy number, the low magnitude of the
deviations for most of the SCNAs interfered with precise
characterization. We conjecture that the vast majority of
the SCNAs we observed were present in less than 10% of
the cell population in each sample. It is worth emphasizing
that even when SCNAs displayed small BAF and LRR devi-
ations, the statistical evidence for AI, based on the phase
concordance, was still exceptionally high for all of the
called events. We also note that a majority of large SCNAs
we discovered coincided with chromosomes even though
the HMM is applied to ordered marker data for all 22 auto-
somes concatenated into a single input vector without
regard to specific marker locations or chromosomal anno-
tation; this observation favors a molecular rather than a
stochastic source.
In previous analyses, SCNA prevalence (that is, the
frequency of individuals with one or more SCNAs) was
strongly positively associated with age. In our results, the
prevalence of SCNAs among individuals older than 80
years of age was approximately 12% (Figure 4). Although
the sample size at this age range is modest, the increase
in SCNA rate compared to that in middle age is quite large.
To formally examine the relationship between age and our
observed SCNAs while accounting for the possible con-
founding effect of samples being genotyped in different
studies, we applied the Mantel extension test for trend by
using only the 20,727 samples derived from blood DNA
from individuals for whom we had age information. We
found that age was a significant predictor of the presence
of one or more observed SCNAs (p value ¼ 1026). We
generally detected two to four times as many SCNAs per
age category as Laurie et al. did. It is interesting to note
that low-cell-fraction clones seemingly went undetected
in every age category.
These results corroborate and augment the current
observational evidence of somatic mosaicism in appar-
ently healthy tissue and suggest that the rate of mosaicism
in phenotypically normal individuals is higher than was
reported in recent large-scale studies. Our analysis was spe-
cifically motivated to detect mosaicism from low-cell-frac-
tion mutations. This part of the landscape of somatic mu-
tations is important because it is likely that the majority of
somatic mutations exist at low cell fractions. Indeed, our
analysis supports this notion even though lower-fre-
quency mutations are more difficult to detect. By using a
haplotype-based method that leverages the dependence
among BAFs in imbalanced regions, we detected a larger
number of low-cell-fraction aberrations than in previous
analyses of these data. Even so, low-cell-fraction SCNAs
create a weak signal that is difficult to discern from back-
ground noise, and when they cover short genomic regions
there is insufficient statistical evidence for their detection.rican Journal of Human Genetics 98, 571–578, March 3, 2016 575
Figure 4. Mosaic Rate by Age
The gold numbers below each age bin indicate the sample size for that bin. The numbers above each bar are the number of samples that
fall in that age bin and have at least one SCNA.An analogy is detecting a subtly unfair coin, which is
possible only with a sufficiently large number of coin flips.
In the case of detecting SCNAs with a subtle signal, we
need a large number of informative loci. Thus, to maintain
high specificity in our study, we targeted large aberrations.
Small events with a high cell fraction do create a strong
enough signal that they are also picked up with this
setting. This bias for aberrations of certain sizes and
phase-concordance ranges must be kept in mind when
one interprets the observed distribution of SCNAs—the
lack of observations that are small in size and exhibit low
phase concordance is clearly due to the lack of power to
detect this category of aberrations. We can easily ratio-
nalize that large aberrations will be expected to exist
mostly at low cell fractions because they are more likely
than smaller aberrations to have a negative impact on
cell fitness. Interestingly, we do observe a number of large
SCNAs with cell fractions that are likely to exceed 15%;
these might comprise mutations that increase cell fitness
in the balance, at least for the sampled tissue at the post-
developmental stage of the organism.
Our results support previous reports3,5 of a sharp in-
crease in the rate of detected mosaicism in elderly individ-
uals compared to younger individuals. This observation
may indicate a higher rate of somatic mutation in the
elderly, which is consistent with the hypothesis that muta-
tion rate increases with age as a result of a reduction in
DNA-repair activity or an increase in the incidence of er-
rors (for example, an increase in the incidence of structural
rearrangements and aneuploidy resulting from telomere576 The American Journal of Human Genetics 98, 571–578, March 3attrition19). An alternative explanation is that the muta-
tion rate is largely constant over time but that detectable
mosaicism is associated with age because in older individ-
uals there has been more time for viable mutant clones to
initiate and expand by drift or selection. Further investiga-
tion of mosaicism in youth and middle age, by methods
tuned for low-frequency mosaic mutations, might shed
light on the relative impact of factors influencing somatic
mutation rates.
The nonrandom distribution of SCNAs and mutation
types across the genome suggests highly preferential muta-
tion initiation or selection for or against mutations in
certain regions. Several of the recurrently imbalanced re-
gions include genes that have been associated with cancer.
Because all of the blood samples analyzed were collected
from individuals without diagnosed hematological cancer,
we can conclude that observed aberrations are generally
insufficient to initiate transformation, but how important
are their potential impacts on proliferation? One exciting
possibility is that low-frequency clones can be used as valu-
able early-disease cancer biomarkers. Indeed, Laurie et al.3
established such a relationship in these data, and this has
been observed elsewhere as well.4,7 Although somatic
mutation is a driving force in cancer, the extreme level
of genomic aberration observed in many cancers high-
lights the high level of robustness of the human genome
and supports the notion that sporadic random somatic
mutations can be of little consequence and should be ex-
pected at a low frequency in normal tissues. In fact, math-
ematical modeling demonstrates that large fractions of the, 2016
single-nucleotide mutations observed in tumors of self-
renewing tissues are passenger mutations acquired during
normal tissue maintenance that happened to be carried
by the initiating tumor cell,20 and a recent study found
that the large variation in lifetime risk among cancers of
different tissues is explained in large part by variation in
the number of normal cell divisions among tissues.21
These observations underscore the need for further charac-
terization of the landscape of somatic mutation in normal
tissue to improve our understanding of the significance of
mutations observed in cancer. Because the landscape of
tolerated and functional somatic mutations is likely to
vary by tissue, studies using samples from other tissues
would complement the largely blood-based studies that
have been recently conducted.Supplemental Data
Supplemental data include three figures and four tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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